AU6117000A - Novel polynucleotides and method of use thereof - Google Patents

Novel polynucleotides and method of use thereof

Info

Publication number
AU6117000A
AU6117000A AU61170/00A AU6117000A AU6117000A AU 6117000 A AU6117000 A AU 6117000A AU 61170/00 A AU61170/00 A AU 61170/00A AU 6117000 A AU6117000 A AU 6117000A AU 6117000 A AU6117000 A AU 6117000A
Authority
AU
Australia
Prior art keywords
novel polynucleotides
polynucleotides
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU61170/00A
Inventor
Kevin P. Baker
Audrey Goddard
William I. Wood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AU6117000A publication Critical patent/AU6117000A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU61170/00A 1999-07-26 2000-07-21 Novel polynucleotides and method of use thereof Abandoned AU6117000A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14570199P 1999-07-26 1999-07-26
US60145701 1999-07-26
PCT/US2000/020006 WO2001007611A2 (en) 1999-07-26 2000-07-21 Novel polynucleotides and method for the use thereof

Publications (1)

Publication Number Publication Date
AU6117000A true AU6117000A (en) 2001-02-13

Family

ID=22514171

Family Applications (1)

Application Number Title Priority Date Filing Date
AU61170/00A Abandoned AU6117000A (en) 1999-07-26 2000-07-21 Novel polynucleotides and method of use thereof

Country Status (5)

Country Link
EP (1) EP1196570A2 (en)
JP (1) JP2003505082A (en)
AU (1) AU6117000A (en)
CA (1) CA2378403A1 (en)
WO (1) WO2001007611A2 (en)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020115839A1 (en) * 2000-08-31 2002-08-22 Millennium Pharmaceuticals, Inc. 8797, a novel human galactosyltransferase and uses thereof
WO2001021836A2 (en) * 1999-09-23 2001-03-29 Incyte Genomics, Inc. Molecules for diagnostics and therapeutics
WO2001023562A2 (en) * 1999-09-27 2001-04-05 Eli Lilly And Company Osteoprotegerin regulatory region
EP1233981A4 (en) 1999-11-16 2003-02-12 Merck & Co Inc G-protein coupled receptor
AU1919401A (en) * 1999-11-17 2001-05-30 Lexicon Genetics Incorporated Novel human notch ligand proteins and polynucleotides encoding the same
US6803192B1 (en) 1999-11-30 2004-10-12 Mayo Foundation For Medical Education And Research B7-H1, a novel immunoregulatory molecule
AU784634B2 (en) 1999-11-30 2006-05-18 Mayo Foundation For Medical Education And Research B7-H1, a novel immunoregulatory molecule
WO2001083545A1 (en) * 2000-04-27 2001-11-08 Takeda Chemical Industries, Ltd. Novel proetin and use thereof
WO2003057926A1 (en) 2002-01-08 2003-07-17 Chiron Corporation Gene products differentially expressed in cancerous breast cells and their methods of use
US7700359B2 (en) 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
WO2002020598A1 (en) * 2000-07-28 2002-03-14 Michael Andrew Mcguckin Mucin
US20040115682A1 (en) * 2001-02-15 2004-06-17 Yusuke Nakamura Novel scavenger receptor class a protein
US6518055B2 (en) * 2001-03-26 2003-02-11 Applera Corporation Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
US7794710B2 (en) 2001-04-20 2010-09-14 Mayo Foundation For Medical Education And Research Methods of enhancing T cell responsiveness
MXPA03010069A (en) 2001-05-03 2004-04-02 Childrens Medical Center Sperm-specific cation channel, and uses therefor.
US6809104B2 (en) 2001-05-04 2004-10-26 Tularik Inc. Fused heterocyclic compounds
US20020173459A1 (en) * 2001-05-18 2002-11-21 Pe Corporation (Ny) Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof
WO2002097394A2 (en) 2001-05-31 2002-12-05 Merck & Co., Inc. Rhesus monkey, dog and ferret melanin-concentrating hormone type 2 receptor
AU2002340118B2 (en) 2001-10-04 2007-09-13 Immunex Corporation UL16 Binding protein 4
US8729248B2 (en) 2001-10-22 2014-05-20 Children's Medical Center Corporation Sperm-specific cation channel, CATSPER2, and uses therefor
AU2002364939A1 (en) 2001-10-22 2003-07-09 Board Of Regents, The University Of Texas System Sperm-specific cation channel, catsper2, and uses therefor
WO2004015066A2 (en) 2002-08-07 2004-02-19 Children's Medical Center Corporation Sperm-specific cation channel, catsper-4, and uses therefor
AU2003258056A1 (en) 2002-08-07 2004-02-25 Children's Medical Center Corporation Sperm-specific cation channel, catsper-3, and uses therefor
EA009421B1 (en) 2002-11-06 2007-12-28 Эмджен Инк. Fused heterocyclic compounds
PT2157192E (en) 2003-10-10 2013-11-28 Deutsches Krebsforsch Compositions for diagnosis and therapy of diseases associated with aberrant expression of futrins (r-spondins)
GB0417887D0 (en) 2004-08-11 2004-09-15 Ares Trading Sa Protein
HUE039237T2 (en) 2004-10-06 2018-12-28 Mayo Found Medical Education & Res B7-h1 and pd-1 in treatment of renal cell carcinoma
CA2664738C (en) 2006-09-29 2017-03-07 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
CA2664828A1 (en) 2006-10-20 2008-04-24 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Rspondins as modulators of angiogenesis and vasculogenesis
EP3009148B1 (en) 2007-07-02 2018-08-22 Oncomed Pharmaceuticals, Inc. Compositions and methods for treating and diagnosing cancer
US20120039912A1 (en) 2009-04-15 2012-02-16 Galapagos Sasu Rspondin-3 inhibition in bone disorders
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
AU2012284254B2 (en) 2011-07-15 2015-07-09 Oncomed Pharmaceuticals, Inc. RSPO binding agents and uses thereof
WO2014012007A2 (en) 2012-07-13 2014-01-16 Oncomed Pharmaceuticals, Inc. Rspo3 binding agents and uses thereof
CN106687137A (en) 2014-09-16 2017-05-17 昂考梅德药品有限公司 Treatment of fibrotic diseases
JP2021528988A (en) 2018-07-04 2021-10-28 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト New bispecific agonist 4-1BB antigen-binding molecule
PE20211603A1 (en) 2018-12-21 2021-08-18 Hoffmann La Roche ANTIBODIES THAT JOIN CD3
WO2020141145A1 (en) 2018-12-30 2020-07-09 F. Hoffmann-La Roche Ag Anti-rabbit cd19 antibodies and methods of use
EP3914291A2 (en) 2019-01-22 2021-12-01 F. Hoffmann-La Roche AG Immunoglobulin a antibodies and methods of production and use
EP3931205A1 (en) 2019-02-28 2022-01-05 Genentech, Inc. Antibacterial peptides and methods of use
WO2020208049A1 (en) 2019-04-12 2020-10-15 F. Hoffmann-La Roche Ag Bispecific antigen binding molecules comprising lipocalin muteins
AR119382A1 (en) 2019-07-12 2021-12-15 Hoffmann La Roche PRE-TARGETING ANTIBODIES AND METHODS OF USE
AR119393A1 (en) 2019-07-15 2021-12-15 Hoffmann La Roche ANTIBODIES THAT BIND NKG2D
PE20221906A1 (en) 2019-09-18 2022-12-23 Genentech Inc ANTI-KLK7 ANTIBODIES, ANTI-KLK5 ANTIBODIES, ANTI-KLK5/KLK7 MULTISPECIFIC ANTIBODIES AND METHODS OF USE
US20210230278A1 (en) 2019-12-18 2021-07-29 Hoffmann-La Roche Inc. Antibodies binding to HLA-A2/MAGE-A4
JP2023506956A (en) 2019-12-20 2023-02-20 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト IL-37 fusion proteins and uses thereof
AU2020412609A1 (en) 2019-12-23 2022-06-16 Genentech, Inc. Apolipoprotein L1-specific antibodies and methods of use
AR122569A1 (en) 2020-06-08 2022-09-21 Hoffmann La Roche ANTI-HBV ANTIBODIES AND METHODS OF USE
WO2021255143A1 (en) 2020-06-19 2021-12-23 F. Hoffmann-La Roche Ag Antibodies binding to cd3 and folr1
CR20220629A (en) 2020-06-19 2023-02-17 Hoffmann La Roche Immune activating fc domain binding molecules
TW202216766A (en) 2020-06-19 2022-05-01 瑞士商赫孚孟拉羅股份公司 Antibodies binding to cd3
AU2021291011A1 (en) 2020-06-19 2023-01-05 F. Hoffmann-La Roche Ag Antibodies binding to CD3 and CD19
WO2021255146A1 (en) 2020-06-19 2021-12-23 F. Hoffmann-La Roche Ag Antibodies binding to cd3 and cea
MX2023000339A (en) 2020-07-10 2023-02-09 Hoffmann La Roche Antibodies which bind to cancer cells and target radionuclides to said cells.
PE20231300A1 (en) 2020-07-17 2023-08-24 Genentech Inc ANTI-NOTCH2 ANTIBODIES AND METHODS OF USE
BR112023001740A2 (en) 2020-08-03 2023-02-28 Hoffmann La Roche ANTIGEN-BINDING RECEPTORS, TRANSDUCED T-CELL, ISOLATED POLYNUCLEOTIDE, VECTOR, KIT, METHOD FOR TREAT A DISEASE IN A SUBJECT AND INDUCE LYSIS OF A TARGET CELL AND USE OF ANTIGEN-BINDING RECEPTOR
AR123855A1 (en) 2020-10-20 2023-01-18 Genentech Inc PEG-CONJUGATED ANTI-MERTK ANTIBODIES AND METHODS OF USE
EP4232040A1 (en) 2020-10-20 2023-08-30 F. Hoffmann-La Roche AG Combination therapy of pd-1 axis binding antagonists and lrrk2 inhitibors
CN116507640A (en) 2020-10-28 2023-07-28 豪夫迈·罗氏有限公司 Improved antigen binding receptors
WO2022148853A1 (en) 2021-01-11 2022-07-14 F. Hoffmann-La Roche Ag Immunoconjugates
EP4277705A1 (en) 2021-01-12 2023-11-22 F. Hoffmann-La Roche AG Split antibodies which bind to cancer cells and target radionuclides to said cells
CA3204291A1 (en) 2021-01-13 2022-07-21 F. Hoffmann-La Roche Ag Combination therapy
WO2022169872A1 (en) 2021-02-03 2022-08-11 Genentech, Inc. Multispecific binding protein degrader platform and methods of use
WO2022192647A1 (en) 2021-03-12 2022-09-15 Genentech, Inc. Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
WO2022241082A1 (en) 2021-05-14 2022-11-17 Genentech, Inc. Agonists of trem2
IL308015A (en) 2021-06-09 2023-12-01 Hoffmann La Roche Combination of a particular braf inhibitor (paradox breaker) and a pd-1 axis binding antagonist for use in the treatment of cancer
WO2023288182A1 (en) 2021-07-12 2023-01-19 Genentech, Inc. Structures for reducing antibody-lipase binding
IL309856A (en) 2021-07-14 2024-02-01 Genentech Inc Anti-c-c motif chemokine receptor 8 (ccr8) antibodies and methods of use
WO2023001884A1 (en) 2021-07-22 2023-01-26 F. Hoffmann-La Roche Ag Heterodimeric fc domain antibodies
CN117794953A (en) 2021-08-03 2024-03-29 豪夫迈·罗氏有限公司 Bispecific antibodies and methods of use
WO2023086807A1 (en) 2021-11-10 2023-05-19 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
WO2023094413A1 (en) 2021-11-25 2023-06-01 F. Hoffmann-La Roche Ag Improved antigen binding receptors
AR127887A1 (en) 2021-12-10 2024-03-06 Hoffmann La Roche ANTIBODIES THAT BIND CD3 AND PLAP
WO2023114829A1 (en) 2021-12-15 2023-06-22 Genentech, Inc. Stabilized il-18 polypeptides and uses thereof
TW202340248A (en) 2021-12-20 2023-10-16 瑞士商赫孚孟拉羅股份公司 Agonistic ltbr antibodies and bispecific antibodies comprising them
TW202340251A (en) 2022-01-19 2023-10-16 美商建南德克公司 Anti-notch2 antibodies and conjugates and methods of use
WO2023174838A1 (en) 2022-03-14 2023-09-21 F. Hoffmann-La Roche Ag Modulators of the g3bp2-tau interaction for the treatment of tau associated diseases
WO2023180511A1 (en) 2022-03-25 2023-09-28 F. Hoffmann-La Roche Ag Improved chimeric receptors
WO2023186756A1 (en) 2022-03-28 2023-10-05 F. Hoffmann-La Roche Ag Interferon gamma variants and antigen binding molecules comprising these
TW202402794A (en) 2022-03-28 2024-01-16 瑞士商赫孚孟拉羅股份公司 Improved folr1 protease-activatable t cell bispecific antibodies
WO2023191816A1 (en) 2022-04-01 2023-10-05 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2023198661A1 (en) 2022-04-12 2023-10-19 F. Hoffmann-La Roche Ag Fusion proteins targeted to the central nervous system
WO2023219613A1 (en) 2022-05-11 2023-11-16 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2024015897A1 (en) 2022-07-13 2024-01-18 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2024020432A1 (en) 2022-07-19 2024-01-25 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2024020564A1 (en) 2022-07-22 2024-01-25 Genentech, Inc. Anti-steap1 antigen-binding molecules and uses thereof
WO2024068572A1 (en) 2022-09-28 2024-04-04 F. Hoffmann-La Roche Ag Improved protease-activatable t cell bispecific antibodies
WO2024077239A1 (en) 2022-10-07 2024-04-11 Genentech, Inc. Methods of treating cancer with anti-c-c motif chemokine receptor 8 (ccr8) antibodies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5536637A (en) * 1993-04-07 1996-07-16 Genetics Institute, Inc. Method of screening for cDNA encoding novel secreted mammalian proteins in yeast
US5707829A (en) * 1995-08-11 1998-01-13 Genetics Institute, Inc. DNA sequences and secreted proteins encoded thereby
US5824504A (en) * 1996-09-26 1998-10-20 Elshourbagy; Nabil A. Human 7-transmembrane receptor and DNA

Also Published As

Publication number Publication date
EP1196570A2 (en) 2002-04-17
WO2001007611A3 (en) 2001-08-23
JP2003505082A (en) 2003-02-12
WO2001007611A2 (en) 2001-02-01
CA2378403A1 (en) 2001-02-01

Similar Documents

Publication Publication Date Title
AU6117000A (en) Novel polynucleotides and method of use thereof
AU4520801A (en) Novel substituted phenanthridinones and methods of use thereof
AU3867400A (en) Methods of using bioelastomers
AU2468401A (en) Underreamer and method of use
AU7989400A (en) Compounds and methods
AU3215500A (en) Compounds and methods
AU3917400A (en) Athletic apparatus and method of use
AU715620C (en) Therapeutic methods and uses
AU5800399A (en) Polish composition and method of use
AU5886500A (en) Indolyl-benzimidazole antibacterials, and methods of use thereof
AU5116100A (en) Connector and method of use of the connector
AU9569998A (en) Photo-spectrometers, methods of use and manufacture
AU1083501A (en) Antibiotic-metal complex and methods
AU1812601A (en) Cover member and method of making same
AUPO679297A0 (en) Rheology modification and modifiers
AU7134700A (en) Maize msi polynucleotides and methods of use
AUPP807799A0 (en) Polynucleotide and method
AU1755301A (en) Rollercross-type game and method thereof
AU2207001A (en) Novel compounds and process
AU3725500A (en) Hand-held bidet and method of use
AU5979300A (en) Angiopoietin-6 and uses thereof
AU1459500A (en) Dihydropyridine compounds and methods of use
AU4598400A (en) Method of treatment
AU3476300A (en) Improved mouse and method of using
AU6230499A (en) Method for preparing 2-chloropropionaldehyde and use of the same

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase